Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook
Third-quarter results reflect strong new product sales growth and continued operational excellence, helping mitigate broader market headwinds Pricing pressure was concentrated in North America and Latin America, reflecting an anticipated acetochlor headwind and competitive dynamics on...
Covered in this story
Analyst targets on Corteva
- Goldman Sachs: at $14.4 · target $20 by Oct 2027 · Buy via Investing.com
- Oppenheimer: at $14.4 · target $17 by Oct 2027 · Outperform via Investing.com
- RBC Capital Markets: at $14.4 · target $17 by Oct 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CTVA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Corteva →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.